You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Article info

Article menu
XML
Epidemiology
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Authors

  • Ulf M Geisen Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Dennis K Berner Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Florian Tran Department for Internal Medicine I, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany Institute for Clinical Molecular Biology, Christian-Albrechts-Universitat zu Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Melike Sümbül Department for Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Lena Vullriede Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Maria Ciripoi Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Hayley M Reid Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Annika Schaffarzyk Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Ann C Longardt Department for Pediatrics, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Jeanette Franzenburg Institute for Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Schleswig-Holstein, Germany Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Paula Hoff Endokrinologikum-Gruppe, Berlin, Germany PubMed articlesGoogle scholar articles
  • Jan H Schirmer Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Rainald Zeuner Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Anette Friedrichs Department for Internal Medicine I, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Andrea Steinbach Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Christine Knies medac GmbH, Wedel, Germany PubMed articlesGoogle scholar articles
  • Robert DH Markewitz Institute of Clinical Chemistry, Universitätsklinikum Schleswig-Holstein – Campus Lübeck, Lubeck/Kiel, Germany PubMed articlesGoogle scholar articles
  • Peter J Morrison Department for Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Sascha Gerdes Department for Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Stefan Schreiber Institute for Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Schleswig-Holstein, Germany Medical Department I, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  • Bimba F Hoyer Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Bimba F Hoyer, Medical Department I, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany; Bimba.Hoyer{at}uksh.de
View Full Text

Citation

Geisen UM, Berner DK, Tran F, et al
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
Annals of the Rheumatic Diseases 2021;80:1306-1311.

Publication history

  • Received March 3, 2021
  • Revised March 10, 2021
  • Accepted March 12, 2021
  • First published March 24, 2021.
Online issue publication 
September 13, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.